Diabetes mellitus Medical Services in China

Diabetes mellitus is a chronic, progressive metabolic disorder characterized by persistent hyperglycemia resulting from defects in insulin secretion, insulin action, or both. It is broadly classified into type 1 diabetes (T1D), an autoimmune condition causing near-total beta-cell destruction and absolute insulin deficiency; type 2 diabetes (T2D), the most prevalent form, driven by insulin resistance and relative insulin deficiency; gestational diabetes mellitus (GDM), which develops during pregnancy; and other specific types including monogenic diabetes and secondary forms due to pancreatic disease, endocrinopathies, or medications. Pathogenesis involves complex interactions among genetic susceptibility, epigenetic modulation, environmental triggers (e.g., sedentary lifestyle, ultra-processed diets, chronic stress), and immune dysregulation—particularly in T1D where autoreactive T-cells destroy insulin-producing islet beta cells. In T2D, adipose tissue inflammation, mitochondrial dysfunction in skeletal muscle and liver, and impaired incretin signaling contribute to systemic insulin resistance and progressive beta-cell failure. Globally, diabetes affects over 537 million adults (2023 IDF Atlas), with prevalence projected to rise to 643 million by 2030. China bears the world’s largest diabetes burden—approximately 141 million adults live with the disease, and another 388 million have prediabetes. Key modifiable risk factors include obesity (especially central adiposity), physical inactivity, unhealthy diet high in refined carbohydrates and saturated fats, smoking, and sleep deprivation; non-modifiable risks include age >45 years, family history, history of GDM, polycystic ovary syndrome (PCOS), and certain ethnic backgrounds (e.g., Han Chinese exhibit heightened susceptibility to beta-cell dysfunction at lower BMI thresholds). Uncontrolled diabetes significantly impairs quality of life: patients report higher rates of fatigue, depression, anxiety, sexual dysfunction, and cognitive decline. Microvascular complications—including retinopathy (leading cause of adult-onset blindness), nephropathy (a major cause of end-stage renal disease), and neuropathy (causing pain, foot ulcers, and amputations)—and macrovascular complications such as coronary artery disease, stroke, and peripheral arterial disease substantially increase morbidity and mortality. Early diagnosis, individualized glycemic targets, comprehensive cardiovascular risk management (blood pressure, lipids, antithrombotic therapy), structured diabetes self-management education and support (DSMES), and psychosocial care are essential to preserve function, prevent complications, and sustain long-term well-being.

Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia resulting from defects in insulin secretion, insulin action, or both. Effective management requires a comprehensive, individualized, and multidisciplinary approach coordinated primarily within the Department of Endocrinology. Treatment strategies are stratified according to diabetes type (Type 1, Type 2, gestational, or other specific forms), disease duration, comorbidities, complications, and patient-specific factors including age, lifestyle, socioeconomic status, and treatment preferences.

Conservative (non-pharmacologic) treatment forms the cornerstone of diabetes care—particularly for Type 2 diabetes—and remains essential across all subtypes. Medical nutrition therapy (MNT) is evidence-based and personalized, emphasizing caloric balance, low glycemic index carbohydrates, high-fiber whole grains, lean proteins, and unsaturated fats. Dietary patterns such as the Mediterranean diet and plant-predominant approaches have demonstrated efficacy in improving glycemic control and cardiovascular risk profiles. Structured physical activity—comprising at least 150 minutes per week of moderate-intensity aerobic exercise (e.g., brisk walking, cycling) combined with resistance training twice weekly—is strongly recommended to enhance insulin sensitivity, reduce visceral adiposity, and improve lipid metabolism. Behavioral interventions, including cognitive-behavioral therapy, motivational interviewing, and digital health coaching, support long-term adherence to lifestyle modifications. Smoking cessation and alcohol moderation (<14 g/day for men, <7 g/day for women) are mandatory adjuncts. Continuous glucose monitoring (CGM)-guided lifestyle feedback and structured education programs (e.g., Diabetes Self-Management Education and Support, DSMES) significantly improve HbA1c, reduce hypoglycemia, and empower patients to make informed daily decisions.

Pharmacologic therapy is initiated when conservative measures fail to achieve glycemic targets (typically HbA1c <7.0% for most non-elderly adults; individualized per ADA/EASD guidelines). For Type 1 diabetes, lifelong exogenous insulin is indispensable: basal-bolus regimens (long-acting analogues like insulin glargine U300 or degludec combined with rapid-acting analogues such as lispro or aspart) or sensor-augmented pump therapy (including hybrid closed-loop systems) represent current standards. In Type 2 diabetes, metformin remains first-line unless contraindicated (e.g., eGFR <30 mL/min/1.73 m², severe hepatic impairment). Second-line agents are selected based on comorbidity profiles: SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin) for patients with established atherosclerotic cardiovascular disease (ASCVD), heart failure, or chronic kidney disease (CKD); GLP-1 receptor agonists (e.g., semaglutide, dulaglutide) for those requiring weight loss, ASCVD risk reduction, or renal protection; and DPP-4 inhibitors (e.g., sitagliptin) for lower hypoglycemia risk in frail or elderly populations. Insulin therapy is escalated when oral/injectable agents fail—starting with basal insulin (e.g., insulin detemir), then progressing to basal-bolus or premixed regimens. Emerging agents—including dual GIP/GLP-1 receptor agonists (e.g., tirzepatide)—demonstrate superior glycemic and weight outcomes in clinical trials and are increasingly integrated into treatment algorithms.

Surgical treatment is reserved for select individuals with obesity-related Type 2 diabetes. Metabolic surgery—including Roux-en-Y gastric bypass (RYGB), sleeve gastrectomy (SG), and biliopancreatic diversion with duodenal switch (BPD-DS)—is indicated for adults with BMI ≥40 kg/m² or BMI ≥35 kg/m² with inadequately controlled hyperglycemia despite optimal medical therapy. Surgery induces durable remission (defined as normoglycemia without antihyperglycemic medications for ≥1 year) in up to 60–80% of eligible patients, mediated by enhanced incretin secretion, improved hepatic insulin sensitivity, and reduced adipose inflammation. Preoperative endocrine evaluation, nutritional counseling, and psychiatric screening are mandatory. Postoperative care includes lifelong micronutrient supplementation (vitamin B12, iron, calcium, vitamin D), annual bone density assessment, and ongoing endocrinologic surveillance for glycemic relapse or nutritional deficiencies.

Treatment in China offers distinct advantages rooted in integrated healthcare infrastructure, technological innovation, and policy support. The National Health Commission’s 'Healthy China 2030' initiative prioritizes chronic disease prevention, enabling widespread access to subsidized glucometers, test strips, and insulin analogues via the National Reimbursement Drug List (NRDL). China leads globally in CGM adoption—domestic manufacturers (e.g., iHealth, Foresight) produce affordable, AI-enhanced real-time sensors with seamless integration into WeChat-based telehealth platforms. Endocrinology departments in tier-1 hospitals (e.g., Peking Union Medical College Hospital, Shanghai Ruijin Hospital) operate standardized diabetes centers accredited by the Chinese Diabetes Society (CDS), offering multidisciplinary teams (endocrinologists, certified diabetes educators, dietitians, podiatrists, ophthalmologists) under one roof. Tele-endocrinology services enable rural patients to consult specialists remotely, reducing disparities in care access. Moreover, large-scale pragmatic trials (e.g., the China Cardiometabolic Disease and Cancer Cohort Study) generate region-specific evidence guiding local treatment protocols—such as optimized insulin initiation thresholds in East Asian populations who exhibit greater insulin resistance at lower BMI thresholds.

Recovery and long-term management emphasize sustainability over short-term correction. Patients should perform home blood glucose monitoring as clinically indicated (e.g., multiple daily injections or insulin pump use), interpret trends—not isolated values—and adjust food/activity accordingly. Annual comprehensive assessments include dilated eye exams, urine albumin-to-creatinine ratio (UACR), estimated glomerular filtration rate (eGFR), monofilament foot screening, and lipid panel. Vaccinations (influenza, pneumococcal, hepatitis B, and now updated COVID-19 boosters) are critical given immune dysregulation in diabetes. Psychosocial well-being must be routinely addressed: depression and diabetes distress affect >20% of patients and correlate with poor adherence and outcomes. Family involvement, peer support groups, and culturally adapted mindfulness-based stress reduction programs improve resilience. Finally, patients should carry medical identification, understand sick-day rules (e.g., continuing insulin during illness, checking for ketones in Type 1), and maintain regular follow-up every 3–6 months—or more frequently if unstable. With consistent, evidence-based, and compassionate care, diabetes need not limit quality or longevity: it is a manageable condition where proactive partnership between patient and endocrinology team yields measurable, life-sustaining benefits.